Cychlorphine (N-Propionitrile Chlorphine): An Emerging Benzimidazolone Synthetic Opioid and Its Implications for Overdose Recognition and Management
Open accessThe DOI matches its Crossref record; 6 of the 8 references it cites were found in a registry or an index; 10 of the 33 sources its claims cite were checked for support.
Abstract
Robert B Raffa,1,2 Frank Breve,3 Joseph V Pergolizzi Jr,2,4 Eugene Vortsman,5 Giustino Varrassi61School of Pharmacy, Temple University (Emeritus), Philadelphia, PA, USA; 2Research and Development, Enalare Therapeutics, Mullica Hill, NJ, USA; 3Clinical Pharmacy, Mid Atlantic PharmaTech Consultants, Ventnor City, NJ, USA; 4Anesthesiology, NEMA Research, Naples, FL, USA; 5Emergency Department, Long Island Jewish Medical Center at Northwell Health, New York, NY, USA; 6VIBRO, Fondazione Paolo Procacci, Roma, ItalyCorrespondence: Robert B Raffa, Email robert.raffa@gmail.com
Overview
CoChat Summary
TL;DR
Cychlorphine (N-propionitrile chlorphine) is an emerging benzimidazolone “orphine” synthetic opioid detected in fatal overdoses and toxicology cases, with potent µ-opioid receptor agonism and major detection gaps in standard screens. Naloxone is still expected to work as for other MOR agonists, though repeat dosing may be needed and co-intoxicants can complicate reversal.
Key findings
- Cychlorphine is a benzimidazolone/orphine NSO, not a fentanyl analog, nitazene, or morphinan; CFSRE first detected it in August 2024 with confirmatory identification in September 2024, and DEA reported its first US laboratory detection in Florida in April 2024. By end of February 2026, DEA laboratories had identified it in 22 samples nationally.
- The CFSRE January 2026 alert reported N-propionitrile chlorphine in 25 blood specimens from fatal overdoses—21 in the United States and 4 in Canada—and it was the sole opioid identified in 11 of those 25 cases. NMS Labs tentatively identified it in more than 100 toxicology cases; as of March 2026, at least 24 states reported overdoses or deaths linked to cychlorphine, including 19 confirmed deaths in East Tennessee.
- Preclinical data on chlorphine and related analogs show nanomolar MOR affinity, with chlorphine having the highest binding affinity among the series (Ki = 1.92 nM), potent antinociception, and pronounced respiratory depression; naloxone pre-treatment (6 mg/kg i.p.) only partially reversed respiratory depression for some compounds. Cychlorphine is estimated to be ~10-fold more potent than fentanyl.
- Standard hospital immunoassays and fentanyl/nitazene test strips do not detect benzimidazolone NSOs; LC-MS/MS with validated reference standards is required. The paper states there is no published clinical evidence that naloxone is ineffective for cychlorphine overdose, and the only peer-reviewed human case report—a 36-year-old man with apnea, bradycardia, hypothermia, and partial naloxone response—does not mention pupil findings.
Methods
- The paper is a narrative synthesis/commentary rather than a primary study; no formal methods section, systematic review protocol, or statistical analysis is reported.
- It draws on cited public alerts and surveillance data (CFSRE, DEA, NMS Labs, UNODC), preclinical in vitro/in vivo characterization of brorphine and analogs, and one peer-reviewed human case report.
- Main analysis is narrative integration of pharmacology, forensic detection data, and clinical management considerations for overdose recognition and naloxone use.
Limitations
- Stated in text: no published clinical evidence supports the claim that naloxone is ineffective for cychlorphine; the “naloxone was not able to completely block” finding comes from a pre-treatment blocking design, not rescue administration. No published paper or case report explicitly records pupil size in a cychlorphine overdose victim, and standard immunoassays miss the compound, so deaths are systematically undercounted.
- Stated in text: cychlorphine is not federally scheduled in the United States, and its status under the Federal Analog Act as applied to benzimidazolone structures has not been definitively resolved.
- Evident from text: the clinical and epidemiological conclusions rely heavily on public alerts, surveillance counts, and extrapolation from chlorphine/brorphine analogs to cychlorphine, with limited human clinical data and no primary clinical trial or systematic review.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 3 Not valid · 19 Not checked · 8 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly partial naloxone reversal of cardiorespiratory impairment induced by these analogs in vivo was reported.6”
What the sources say
- Partly supportedcites [6] Vandeputte MM, Bilel S, Tirri M, et al. Elucidating the harm potential of brorphine analogues as new synthetic opioids: synthesis, in vitro, and in vivo characterization. Neuropharmacology. 2024; 260: 110113. doi: 10.1016/j.neuropharm.2024.110113 39154855 sourceExperimental — accuracy not yet measured
Section 3.2.4 reports that naloxone blocked respiratory-rate decreases caused by several analogues, but accelerated rather than alleviated iodorphine’s respiratory effects. The Discussion likewise describes compound-dependent respiratory responses to naloxone. The paper does not report reversal of cardiovascular impairment; its Discussion identifies cardiovascular tests as future work. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, respiratory depression assayed by non-invasive plethysmography was most pronounced for fluorphine, chlorphine, and brorphine;”
What the sources say
- Supportedcites [6] Vandeputte MM, Bilel S, Tirri M, et al. Elucidating the harm potential of brorphine analogues as new synthetic opioids: synthesis, in vitro, and in vivo characterization. Neuropharmacology. 2024; 260: 110113. doi: 10.1016/j.neuropharm.2024.110113 39154855 source
The Discussion (section 4) says that respiratory effects were assessed by non-invasive plethysmography at a fixed 15 mg/kg dose and that effects from orphine and iodorphine were generally less pronounced. The plethysmography results (section 3.2.4) report substantial respiratory changes with brorphine, fluorphine, and chlorphine, supporting the stated comparison. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Confirmatory identification requires liquid chromatography coupled to mass spectrometry (LC-MS/MS) with validated reference standards.9”
What the sources say
- Partly supportedcites [9] Palmquist KB, Truver MT, Shoff EN, Krotulski AJ, Swortwood MJ. Review of analytical methods for screening and quantification of fentanyl analogs and novel synthetic opioids in biological specimens. J Forensic Sci. 2023; 68: 1643– 1661. doi: 10.1111/1556-4029.15282 37221651 sourceExperimental — accuracy not yet measured
The Conclusion (page unavailable) says multistage LC-MS has almost universally become the preferred technique for definitive and confirmatory procedures involving novel synthetic opioids. It does not say LC-MS/MS is required, specify validated reference standards, or address cychlorphine; searches for cychlorphine and validated reference standards found no matching passage. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In vivo, chlorphine and brorphine produce the highest levels of antinociception in mouse hot-plate and tail-flick assays.”
What the sources say
- Partly supportedcites [6] Vandeputte MM, Bilel S, Tirri M, et al. Elucidating the harm potential of brorphine analogues as new synthetic opioids: synthesis, in vitro, and in vivo characterization. Neuropharmacology. 2024; 260: 110113. doi: 10.1016/j.neuropharm.2024.110113 39154855 sourceExperimental — accuracy not yet measured
The Results (§3.2.1) report that chlorphine and brorphine alone reached maximum antinociception in the mouse tail-pinch test. But this paper’s assays were tail pinch and tail withdrawal, not hot plate and tail flick; in tail withdrawal, orphine’s maximum effect was comparable to theirs. The Discussion (§4) mentions hot-plate and tail-flick findings from earlier studies, not from this paper’s mouse experiments. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and, concerningly, for some compounds, pre-treatment with naloxone (6 mg/kg i.p.) only partially reversed respiratory depression, indicating possible non-opioid contributions to toxicity or receptor kinetics that differ from classical opioids.6”
What the sources say
- Partly supportedcites [6] Vandeputte MM, Bilel S, Tirri M, et al. Elucidating the harm potential of brorphine analogues as new synthetic opioids: synthesis, in vitro, and in vivo characterization. Neuropharmacology. 2024; 260: 110113. doi: 10.1016/j.neuropharm.2024.110113 39154855 sourceExperimental — accuracy not yet measured
The Methods (section 2.4.2) confirm naloxone pretreatment at 6 mg/kg i.p., and the Abstract says it could not reverse respiratory depression for some compounds. But the Results (section 3.2.4) describe full blockade of the respiratory-rate decrease for four compounds and an expedited, rather than partially reversed, effect for iodorphine. The Discussion treats differing receptor kinetics and possible non-opioid contributions as explanations requiring further investigation, not established causes. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
19 more claims · 2 with their cited sources checked
Create a free account to see all 38 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 3
Citations
Cites
Old Drugs and New Challenges: A Narrative Review of Nitazenes
Pergolizzi Jr, J., Raffa, R., LeQuang, J. A. K., Breve, F., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.40736 · Cited by 81
Self-citationPapsun, D. M., Krotulski, A. J., & Logan, B. K. (2022) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000787 · Cited by 51
Palmquist, K. B., Truver, M. T., Shoff, E. N., Krotulski, A. J., & Swortwood, M. J. (2023) · Journal of Forensic Sciences · doi:10.1111/1556-4029.15282 · Cited by 39 · cited 1×
“8,9 Confirmatory identification requires liquid chromatography coupled to mass spectrometry (LC-MS/MS) with validated reference standards.”
Vandeputte, M. M., Bilel, S., Tirri, M., Corli, G., Bassi, M., Layle, N. K., Fantinati, A., Walther, D., Iula, D. M., Baumann, M. H., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110113 · Cited by 19 · cited 1×
“Based on in vitro pharmacology showing MOR full agonism with no significant biased signaling, 6 in the absence of counter-evidence, cychlorphine is expected to respond to naloxone as any other MOR agonist does.”
Non-fatal opioid overdose associated predominantly with the benzimidazolone, cychlorphine
Sprague, J. E., Toms, J. A., & Ratermann, C. F. (2026) · Clinical Toxicology · doi:10.1080/15563650.2025.2594070 · Cited by 8
Dugues, P., Robin, T., Bellouard, M., Chenorhokian, S., Triguel, M., Pfau, G., Feng, C., Cherki, S., Herbette, G., Alvarez, J. C., et al. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1428 · Cited by 6
Cited by
Kutzler, J., Postupka, A., & Auwärter, V. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04546-1 · Cited by 1
Gameli, P. S., Kronstrand, R., & Gréen, H. (2026) · Research Square · doi:10.21203/rs.3.rs-11241883/v1
Metadata
- Authors
- Raffa, R. B., Breve, F., Pergolizzi, J. V., Vortsman, E., & Varrassi, G.
- Affiliations
- Temple University (US)
- Nema Research (United States) (US)
- Northwell Health (US)
- Fondazione Paolo Procacci (IT)
- Corresponding author
- Raffa, Robert B
- Venue
- Journal of Pain Research
- Publisher
- Informa UK Limited
- Published
- 2026-07
- Volume
- Volume 19
- Pages
- 1-3
- ISSN
- 1178-7090 (ISSN-L)
- PMC
- PMC13367459
- OpenAlex
- W7167795840
- Cited by
- 2
- References
- 8
- Citations by year
- 2026: 2
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Pain Research (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- benzimidazolone, synthetic opioids, opioid overdose, overdose management, opioid analgesics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.